RemedyOne

It’s been a little over 6 months since Paxlovid received emergency use authorization. Writing for pharmaphorum, RemedyOne EVP of clinical services Robert Louie explores what we’ve learned about the Covid-19 drug so far this year and what questions remain.

Six months after authorization, what do we know about Paxlovid? - It has now been over six months since the FDA authorized Paxlovid in December 2021 “for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing who are also at high risk...

RemedyOne's in house team of pharmacy rebate experts and clinicians are continually creating strategies, and identifying opportunities to discover additional savings within your rebate programs.

We don't just consider cost - we always balance our recommendations against clinical efficacy and patient care.

See how our in house team of pharmacy experts can help you cut through the complexity of your formulary management at: https://hubs.li/Q019-zy10